Literature DB >> 12943481

Cost-benefit analysis of ivermectin, permethrin and benzyl benzoate in the management of infantile and childhood scabies.

Mervyn L Elgart1.   

Abstract

In the US, 6% sulfur in petrolatum has been the most frequently administered treatment for infantile scabies. It appears to be safe but there is no literature containing a large series of patients on which to base that determination. In the UK, benzyl benzoate is the approved product. Benzyl benzoate is rarely used in the US at the present time. 5% Permethrin is an excellent substitute and has many advantages. It appears to be quite safe in infants, although it is more expensive than other products. It remains present on the skin for several days, therefore protecting against reinfestation. Ivermectin is a systemic drug which is assumed to be safe in infants, although it requires repeated doses and does not protect against reinfestation. In the opinion of the author, 5% permethrin is the best treatment for scabies in infants and young children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943481     DOI: 10.1517/14656566.4.9.1521

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Sarcoptes scabiei (Acari: Sarcoptidae) mite extract modulates expression of cytokines and adhesion molecules by human dermal microvascular endothelial cells.

Authors:  B Laurel Elder; Larry G Arlian; Marjorie S Morgan
Journal:  J Med Entomol       Date:  2006-09       Impact factor: 2.278

2.  Modulation of human dermal microvascular endothelial cells by Sarcoptes scabiei in combination with proinflammatory cytokines, histamine, and lipid-derived biologic mediators.

Authors:  B Laurel Elder; Larry G Arlian; Marjorie S Morgan
Journal:  Cytokine       Date:  2009-06-11       Impact factor: 3.861

3.  A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions.

Authors:  Naomi van der Linden; Kees van Gool; Karen Gardner; Helen Dickinson; Jason Agostino; David G Regan; Michelle Dowden; Rosalie Viney
Journal:  PLoS Negl Trop Dis       Date:  2019-03-08

Review 4.  Scabies: Advances in Noninvasive Diagnosis.

Authors:  Giuseppe Micali; Francesco Lacarrubba; Anna Elisa Verzì; Olivier Chosidow; Robert A Schwartz
Journal:  PLoS Negl Trop Dis       Date:  2016-06-16

5.  Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.

Authors:  Angelica Lindén Hirschberg; Pedro Sánchez-Rovira; Jesús Presa-Lorite; Miriam Campos-Delgado; Miguel Gil-Gil; Elisabet Lidbrink; Javier Suárez-Almarza; Concepción Nieto-Magro
Journal:  Menopause       Date:  2020-05       Impact factor: 3.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.